Coxsackie-Virus-B4-Injeel D 15, D 30, D 200 0.367 ml each.
Coxsackie-Virus-B4-Injeel forte D 10, D 15, D 30, D 200 0.275 ml each.
Coxsackie-Virus-B4 D 6 as single potency.
The immunologically classified types A9 and B4 are responsible for a series of viral diseases. The vital point is that the coxsackie virus can occur both as precursor and substitute for the influenza and poliomyelitis viruses. In the case of obscure and therapy-resistant infections, the coxsackie virus should always be borne in mind. Coxsackie-Virus-A9-Injeel has proved especially valuable in enteric diseases, e.g. gastro-intestinal affections such as gastritis, duodenitis, and particularly, colitis mucosa et ulcerosa (the optimum treatment is by local injection in the twentieth point of the colon, which lies in the nasolabial sulcus); colon irritabile, chronically recurrent intestinal infections; further, affections of the urinary passages such as cystopyelitis, urethritis, cystalgia, prostatitis, epididymitis, sinusitis, conjunctivitis, laryngitis, sinobronchial syndrome, bronchial asthma.
Coxsackie-Virus-B4-Injeel is indicated especially for the sequelae of central affections, e.g. for the conditions after meningitis or pseudomeningitis, after excephalitis and the related mental symptoms, including depression, somnipathy, headaches, etc.